NOVERA COMPOUNDS

Semaglutide 2mg

Coming soon
Purity Guarantee

Semaglutide 2mg

Sign in to view pricing and purchase this product.

Log In Sign Up

Coming Soon

This peptide will be available soon.

Quantity Discount (%) Price
1 - 5 — $38.00
6 - 10 2.63 % $37.00
11 - 20 5.26 % $36.00
21+ 7.89 % $35.00

Why choose Novera Compounds peptides

Research-grade Quality

Every compound is manufactured to research-grade standards and intended strictly for laboratory and research use. Consistent quality you can build a reproducible protocol around.

Documented and traceable

  • Batch number on every vial

  • Published Certificates of Analysis

  • Purity verified by third-party testing

Handled and shipped with care

Temperature-sensitive compounds are stored and shipped under controlled conditions, so material arrives in the state your research requires. Expert support on hand at every step.

About the product

Semaglutide (2 mg) is a synthetic peptide analog derived from glucagon-like peptide-1 (GLP-1). It features structural modifications designed to support extended activity in controlled environments. With a molecular weight of 4113.6 g/mol, this compound is typically supplied as a high-purity, lyophilized powder in vial format.

Semaglutide has been studied for its role in metabolic signaling and glucose regulation, particularly how peptide-based compounds interact with biological systems involved in energy balance and nutrient processing.

Semaglutide (2 mg) Key Features & Specs

  • Subcategory: Weight Loss & Metabolic Peptides
  • Strength: 2 mg
  • CAS: 910463-68-2
  • Chemical Formula: C₁₈₇H₂₉₁N₄₅O₅₉
  • Molecular Weight: 4113.6 g/mol
  • Peptide Sequence: H-His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(AEEAc-AEEAc-γ-Glu-17-carboxyheptadecanoyl)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-OH
  • Synonyms: NN9535

For laboratory research use only.

Semaglutide (2 mg) Research Uses

Semaglutide (2 mg) has been studied for its role in metabolic regulation and energy balance. Research often focuses on how this peptide influences glucose handling, appetite signaling, and nutrient utilization.

Investigations typically examine its role in cellular communication related to endocrine function and metabolic homeostasis. Ongoing research aims to understand peptide-driven signaling within metabolic systems.

Semaglutide (2 mg) Insights & Observed Findings

Preclinical and in vitro studies involving Semaglutide (2 mg) have used carefully controlled dosing, often within microgram-to-milligram ranges, depending on study design. Observations focus on measurable changes in metabolic markers, such as glucose-related parameters and signaling activity.

Findings from metabolic research indicate consistent engagement with biological systems linked to energy regulation. However, outcomes vary based on experimental models, administration protocols, and environmental conditions in laboratory settings.

Semaglutide (2 mg) Handling & Storage

Store Semaglutide (2 mg) at –20°C in a controlled laboratory environment, protected from light and moisture to maintain integrity.

Once reconstituted using appropriate sterile techniques, the solution should be kept refrigerated at 2–8°C and handled in accordance with strict laboratory protocols. Avoid repeated freeze-thaw cycles, and ensure proper labeling and documentation for all prepared samples.

Compliance Notice: This product is intended for laboratory research use only and is not approved for human or veterinary use. It is not intended for diagnostic, therapeutic, or clinical applications. Any reference to biological activity or potential effects is based solely on preclinical or in-vitro findings and should not be interpreted as validated clinical outcomes. Researchers are responsible for ensuring proper handling, storage, and disposal in accordance with institutional, federal, and international guidelines.

References

  1. Lau J, Bloch P, Schäffer L, et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J Med Chem. 2015;58(18):7370-7380. doi:10.1021/acs.jmedchem.5b00726
  2. Liu QK. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists. Front Endocrinol (Lausanne). 2024;15:1431292. Published 2024 Jul 24. doi:10.3389/fendo.2024.1431292
  3. Loomba R, Abdelmalek MF, Armstrong MJ, et al. Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8(6):511-522. doi:10.1016/S2468-1253(23)00068-7
  4. Mahapatra MK, Karuppasamy M, Sahoo BM. Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes. Rev Endocr Metab Disord. 2022;23(3):521-539. doi:10.1007/s11154-021-09699-1
  5. Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. Front Endocrinol (Lausanne). 2019;10:155. Published 2019 Apr 12. doi:10.3389/fendo.2019.00155